Are you "Profiting from the Pros?"
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Weakness Seen in Auxiliam Pharmaceutical (AUXL) Estimates: Should You Stay Away?
May 08, 2014
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Auxiliam Pharmaceutical Inc. , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in AUXL.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 1 estimate moving down in the past 30 days, compared with no upward revision. This trend has caused the consensus estimate to trend lower, going from 60 cents a share a month ago to its current level of 32 cents.
Also, for the current quarter, Auxiliam has seen 1 downward estimate revision versus no revision in the opposite direction, dragging the consensus estimate down to 2 cents a share from 10 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 21.86% in the past month.
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.
If you are still interested in the Med-Drugs industry, you may instead consider some better-ranked stocks including include Enanta Pharmaceuticals, Inc. ( ENTA), Spectrum Pharmaceuticals, Inc. ( SPPI) and Ariad Pharmaceuticals Inc. ( ARIA). Among these stocks Enanta and Spectrum hold a Zacks Rank #1(Strong Buy) and Ariad holds a Zacks Rank #2 (Buy). With favorable Zacks Ranks, these stocks may be better selections at this time.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>